Blog · Safety · Published 2026-08-09
Tirzepatide & Semaglutide Dosage Charts (2026): Standard Titration — and What Charts Don't Tell You
The FDA-labeled tirzepatide schedule starts at 2.5 mg weekly for 4 weeks, then steps 5 → 7.5 → 10 → 12.5 → 15 mg, each held at least 4 weeks as tolerated; maintenance is wherever you and your prescriber stop (5, 10, and 15 mg are the labeled maintenance tiers). The semaglutide (Wegovy) schedule runs 0.25 → 0.5 → 1 → 1.7 → 2.4 mg weekly across 16-plus weeks — and 2026 added a labeled 7.2 mg high-dose tier (Wegovy HD, approved March 19). Those are the anchor charts. Everything else you'll find — including "compounded semaglutide dosage charts" — is a variation on them, and the variations are where errors live.
Why compounded dosage charts differ — and when that's a red flag
Compounded programs legitimately mirror the labeled schedules; some also market slower ramps or intermediate steps (the entire microdosing conversation lives here). What a chart can't do is set your dose — that's the prescriber's call against your response and tolerability — and what no chart survives is a concentration change: compounded vials come in different mg/mL, so the same chart row means a different syringe draw on different vials. That's the mechanism behind most of FDA's 730+ compounded-tirzepatide error reports, and why our vial-math guide insists: prescribed mg ÷ label mg/mL = mL, recomputed on every fill. A program that hands you a units chart without your vial's concentration on it is a program to question.
Dose and price move together — check both charts
Titration has a billing consequence: on dose-scaled programs the maintenance months cost more than the starter months, which is how a "$199" advertisement becomes a $289 reality by 10 mg — mechanics in the dose-surcharge explainer. Dose-flat programs (NexLife's $215/$186 tirzepatide and $165/$145 semaglutide structures are the captured examples) price every chart row identically. Before starting a titration you'll be on for months, get two things in writing: the price at your target maintenance dose, and the concentration of the vials they'll ship. The tirzepatide and semaglutide hubs carry the dose-behavior column for every ranked program.
Frequently asked questions
What is the standard tirzepatide dosage schedule?
Per FDA labeling: 2.5 mg weekly for 4 weeks, then 5, 7.5, 10, 12.5, and 15 mg in steps of at least 4 weeks as tolerated, with 5/10/15 mg as labeled maintenance tiers. Your prescriber sets the actual path.
What is the semaglutide dosage chart for weight loss?
Wegovy labeling: 0.25 → 0.5 → 1 → 1.7 → 2.4 mg weekly over 16-plus weeks; a 7.2 mg high-dose tier (Wegovy HD) was approved March 19, 2026. Compounded programs generally mirror this ramp.
Why do compounded dosage charts show units instead of mg?
Because syringes measure volume. Units only mean something at a specific concentration (mg/mL) — which changes between compounded vials. Any chart without your vial's concentration attached is incomplete and unsafe to follow.
Does my price change as I move up the chart?
On dose-scaled programs, yes — maintenance doses bill higher. Dose-flat programs charge the same at every row. The ranked hubs show which is which for every tracked program.
Primary sources
FDA prescribing information for Zepbound/Mounjaro and Wegovy (including the March 2026 7.2 mg approval); FDA adverse-event communications on compounded dosing errors.
Independent & transparent
Independently operated by US Peptides Partners LLC. Rankings are editorial, computed from published pricing under the methodology, and are not for sale. Outbound provider links carry referral-tracking tags; no arrangement changes a ranking — if a provider out-scores the current leader on captured figures, the ranking changes.